Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on June 16, 2025
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
GlobeNewswire
·
June 16, 2025
BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND to initiate a Phase 1 clinical …
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
GlobeNewswire
·
June 16, 2025
LONDON and PHOENIX, June 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has …
Solera HALO™ Platform Adds Rapid Configurability Tool for Integrated Digital Health Networks
GlobeNewswire
·
June 16, 2025
PHOENIX, June 16, 2025 (GLOBE NEWSWIRE) -- Solera Health, the premier digital health delivery company offering affordable, accessible, and effective digital healthcare solutions, today announced enhancements to its HALO Platform. The latest enhancements …
Psychemedics Releases 2025 Workforce Insights Report
GlobeNewswire
·
June 16, 2025
DALLAS, June 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, today announced the release of its second annual Workforce Insights Report, providing a comprehensive look at the evolving drug …
3Daughters to Lead Panel at BIO International Convention on Patient Reported Outcomes that Includes FDA Division Director
GlobeNewswire
·
June 16, 2025
BOSTON, June 16, 2025 (GLOBE NEWSWIRE) -- 3Daughters, Inc., a clinical development company fueling revolutionary healthcare for women, is proud to announce its founder and CEO, Mary Beth Cicero, will moderate a breakout session at this week’s annual BIO …
INVO Fertility’s Wisconsin Clinic Recognized on Newsweek’s List of America’s Best Fertility Clinics for 2025
GlobeNewswire
·
June 16, 2025
MIDDLETON, Wis. and SARASOTA, Fla., June 16, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on expanding access to advanced treatment through the establishment, …
Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston
GlobeNewswire
·
June 16, 2025
Ramat Gan, Israel, June 16, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory …
Bon Natural Life Announces Distribution Agreement with Tianjin Merrill-Youli Trading Co., Ltd.
GlobeNewswire
·
June 16, 2025
XI’AN, China, June 16, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) (“Bon” or the “Company”), a leading bio-ingredient solutions provider for natural, health, and personal care industries, today announced a non-exclusive sales …
SS Innovations Announces Successful Completion of First Robotic Cardiac Surgery in the Western Hemisphere Utilizing the Company’s SSi Mantra 3 Surgical Robotic System
GlobeNewswire
·
June 16, 2025
FORT LAUDERDALE, Fla., June 16, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and …
Syncromune® Appoints Industry Veteran Kerri-Ann Millar as Chief Financial Officer to Advance Corporate Growth Initiatives and Clinical Development Program
GlobeNewswire
·
June 16, 2025
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, June 16, 2025 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company pioneering SYNC-T, an in situ personalized combination immunotherapy platform for solid tumor cancers, today …
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
GlobeNewswire
·
June 16, 2025
Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV- …
Empty Capsules Market Set for US$4.2B by 2029 — What Should Pharma and Nutraceutical Leaders Know?
GlobeNewswire
·
June 16, 2025
Delray Beach, FL, June 16, 2025 (GLOBE NEWSWIRE) -- The global empty capsules market is entering a pivotal phase—set to grow from US$3.1 billion in 2024 to US$4.2 billion by 2029, driven by evolving drug delivery technologies, booming nutraceutical demand, …
Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
GlobeNewswire
·
June 16, 2025
Inclusion reflects continued growth and momentum in the company’s mission to transform the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) CHICAGO and FORT WORTH, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: …
PetMed Express, Inc. Announces Preliminary Fourth Quarter and FY 2025 Results and Filing of Form 12b-25
GlobeNewswire
·
June 16, 2025
DELRAY BEACH, Fla., June 16, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced preliminary fourth quarter and fiscal year 2025 results and filed Form 12b-25, Notification of Late Filing …
Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer
GlobeNewswire
·
June 16, 2025
MORRISTOWN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTC:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B …
Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel
GlobeNewswire
·
June 16, 2025
CINCINNATI, Ohio, June 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health …
Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032
GlobeNewswire
·
June 16, 2025
FLORHAM PARK, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the U.S. …
MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity
GlobeNewswire
·
June 16, 2025
GLP-1/GIP receptor co-agonist designed to be highly potent and for once-monthly administration based on MBX’s novel PEP™ platform technology Phase 1 trial of MBX 4291 is expected to initiate in Q3 2025 CARMEL, Ind., June 16, 2025 (GLOBE NEWSWIRE) -- MBX …
Osmol Therapeutics E.U. Patent Allowance for Novel Therapy Targeting Chemotherapy-induced Neuropathy
GlobeNewswire
·
June 16, 2025
NEW HAVEN, Conn., June 16, 2025 (GLOBE NEWSWIRE) -- Osmol Therapeutics, a privately held clinical-stage biopharmaceutical company focused on developing preventative treatments for chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced …
Extendicare Announces June 2025 Dividend of C$0.042 per Share
GlobeNewswire
·
June 16, 2025
MARKHAM, Ontario, June 16, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of June 2025, which is payable on July …